Uptown Research Institute congratulates Compass Pathways on their successful year in 2025. With promising results for their investigational product, COMP360, Compass Pathways in on their way to developing the first FDA approved psychedelic medication for people living with treatment-resistant depression, and for people living with post-traumatic stress disorder. As one of the clinical research sites involved with studying COMP360, Uptown Research Institute is proud to play a role in researching and developing novel treatments for people suffering from symptoms of mental illness. We look forward to continuing our work with Compass Pathways.
Follow the link below to read the full article:
https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights/default.aspx